Article Details
Retrieved on: 2024-05-16 13:56:15
Tags for this article:
Click the tags to see associated articles and topics
Summary
Avata Biosciences, a biopharma company formerly Sapient Therapeutics, is developing SAP-021, a solid-dose cannabidiol drug for epilepsy. The company, involving ex-GW Pharmaceuticals staff, aims to rival Epidiolex® in treating Lennox-Gastaut and Dravet syndromes.
Article found on: cannabishealthnews.co.uk
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here